From October 6–8, Ori Biotech attended the Alliance for Regenerative Medicine’s Cell & Gene Meeting on the Mesa in Phoenix, Arizona.
The annual meeting brought together leaders from across the cell and gene therapy ecosystem — developers, investors, and partners — to discuss how the field scales for widespread patient impact.
On Monday, October 6, Ori’s CEO Jason C. Foster led an expert panel titled “The New Standard for CGT Manufacturing – Flexibility and Scalability.” He was joined by Taby Ahsan (City of Hope), Kenneth Harris (OmniaBio), Andrew Snowden (Johnson & Johnson Innovative Medicine), and Tom Wilton (Children’s Hospital of Philadelphia). Together they explored how flexibility, scalability, and collaboration are shaping the next era of CGT manufacturing.
Later that morning, Jason hosted a fireside chat with Tom Whitehead, President and Co-Founder of the Emily Whitehead Foundation — and father to Emily, the first pediatric patient treated with CAR-T therapy. Tom’s reflections on access, collaboration, and the operational challenges that still stand between discovery and delivery offered a powerful reminder of why this work matters.
Throughout the week, the Ori team welcomed partners and colleagues to our private meeting room for data-first discussions on IRO® — including new fluid dynamics results, total cost of ownership insights, and how robust servicing at scale supports real-world manufacturing needs.
We closed out the meeting with an evening of conversation and connection in the Cottage Courtyard, celebrating the collaboration that continues to drive progress across the field.
A huge thank you to everyone who joined us at #CGMesa25 — for the insightful discussions, shared purpose, and commitment to making advanced therapies more accessible for every patient who needs them.